Dicerna Pharmaceuticals: Q2 Earnings Insights
Shares of Dicerna Pharmaceuticals (NASDAQ:DRNA) fell 0.2% in pre-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share were down 23.26% year over year to ($0.53), which missed the estimate of $0.41.
Dicerna Pharmaceuticals Q2 EPS $(0.53) Misses $0.41 Estimate, Sales $41.34M Miss $91.29M Estimate
Dicerna Pharmaceuticals (NASDAQ:DRNA) reported quarterly losses of $(0.53) per share which missed the analyst consensus estimate of $0.41 by 229.27 percent. This is a 23.26 percent decrease over losses of $(0.43) per
Citigroup Downgrades Dicerna Pharmaceuticals to Neutral, Announces $32 Price Target
Citigroup analyst Yigal Nochomovitz downgrades Dicerna Pharmaceuticals (NASDAQ:DRNA) from Buy to Neutral and announces $32 price target.
Earnings Scheduled For August 9, 2021
Companies Reporting Before The Bell
• Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 per share on revenue of $215.17 million.
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in, triggering stock-specific moves, while clinical readouts also moved stocks during the week.
Mid-Afternoon Market Update: Dow Gains 140 Points; Spectrum Pharmaceuticals Shares Plummet
Toward the end of trading Friday, the Dow traded up 0.40% to 35,204.21 while the NASDAQ fell 0.41% to 14,833.72. The S&P also rose, gaining 0.16% to 4,435.97.